Table 2 Patient characteristics upon stratification into two groups by the rate of reduction in thyroid volume

From: The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma

 

High reduction rate group

Low reduction rate group

P -value

Gender

 Female/male

5/3

2/7

0.234

Age, years

 Median (range)

63 (44–69)

59 (23–78)

0.797

Sunitinib Tx, cycles

 Median (range)

13.5 (6–23)

2 (1–6)

0.001

ORR

 CR/PR

7

2

 

 SD

1

2

 

 PD

0

5

0.012

50% PFS, months

Not reach(⩾14.9)

2.3

0.004

Thyroid status at baseline

 Hypothyroidism

3

1

 

 Euthyroid

4

8

 

 Unknown

1

0

0.243

TSH at baseline, mIU l–1

 Median (range)

3.62 (0.61–10.14)

1.57 (0.52–8.65)

0.314

Thyroid volume at baseline, ml

 Median (range)

13.0 (7.8–18.5)

13.6 (5.8–21.0)

0.797

Thyroid status during

 Sunitinib-Tx

Hypothyroidism

8a

1

 

Euthyroid

0

8

0.001

Maximum TSH during

 Sunitinib-Tx, mIU l–1

Median (range)

37.84 (4.69–230.89)

3.51 (1.73–12.72)

0.001

Supplement of L-T4

 During sunitinib-Tx

7

1

0.008

  1. Abbreviations: CR=complete response; ORR=objective response rate; PD=progressive disease; PFS=progression-free survival; PR=partial response; SD=stable disease; TSH=thyroid stimulating hormone; Tx=therapy.
  2. aFour patients experienced hyperthyroidism before hypothyroidism.